Interpace Biosciences, Inc. has taken a significant step towards enhancing its market position by filing an amended registration statement to offer 3.1 million shares of common stock. This move is crucial as the company aims to transition from the OTC market to a listing on the Nasdaq Capital Market. The public offering is expected to occur as soon as practicable after the effective date of the registration statement.

The offering price is estimated to be between $6.00 and $7.00 per share, with the last reported sale price of its common stock on the OTC market being $5.72 per share. The final price will be determined based on various factors, including market conditions and the company's performance. This offering is a firm commitment underwritten offering, indicating strong backing from underwriters.

Interpace Biosciences, Inc. operates in the surgical and medical instruments and apparatus industry, classified under SIC code 3841. The company has been working to improve its visibility and operational efficiency, and this public offering is part of its strategy to raise capital for future growth initiatives.

As a smaller reporting company, Interpace is subject to different reporting requirements, which may allow it to streamline its operations as it grows. The company has expressed confidence that it will meet the standards for listing on Nasdaq, although it acknowledges that no assurance can be given regarding the approval of its listing application.

In the filing, Interpace indicated that it has granted underwriters an option to purchase an additional 465,000 shares to cover over-allotments, further demonstrating its commitment to ensuring a successful offering. The anticipated proceeds from this offering will be pivotal for the company as it seeks to expand its capabilities and market reach.

This development is particularly relevant in the context of the surgical and medical instruments industry, where competition is fierce and innovation is key. By potentially moving to the Nasdaq, Interpace aims to enhance its profile among investors and stakeholders, positioning itself for future growth and development.

The filing does not specify what happens next, but the company is expected to continue its preparations for the public offering while awaiting Nasdaq's decision on its listing application.